Abstract:The gut microbiota and bile acid metabolism are key determinants of the response of inflammatory bowel disease to biologic therapy. However, the molecular mechanisms underlying the interactions between the response to anti-α4β7-integrin therapy and the gut microbiota and bile acid metabolism remain unknown. In this research, we investigated the role of gut microbiota-related bile acid metabolism on the response to anti-α4β7-integrin therapy in a humanized immune system mouse model with colitis induced by 2,4,6-trinitrobenzene sulfonic acid. We found that anti-α4β7-integrin significantly mitigated intestinal inflammation, pathological symptoms, and gut barrier disruption in remission-achieving colitis mice. Whole-genome shotgun metagenomic sequencing demonstrated that employing baseline microbiome profiles to predict remission and the treatment response was a promising strategy. Antibiotic-mediated gut microbiota depletion and fecal microbiome transplantation revealed that the baseline gut microbiota contained common microbes with anti-inflammatory effects and reduced mucosal barrier damage, improving the treatment response. Targeted metabolomics analysis illustrated that bile acids associated with microbial diversity were involved in colitis remission. Furthermore, the activation effects of the microbiome and bile acids on FXR and TGR5 were evaluated in colitis mice and Caco-2 cells. The findings revealed that the production of gastrointestinal bile acids, particularly CDCA and LCA, further directly promoted the stimulation of FXR and TGR5, significantly improving gut barrier function and suppressing the inflammatory process. Taken together, gut microbiota-related bile acid metabolism-FXR/TGR5 axis may be a potential mechanism for impacting the response to anti-α4β7-integrin in experimental colitis. Thus, our research provides novel insights into the treatment response in inflammatory bowel disease.

Effect of gut flora mediated‐bile acid metabolism on intestinal immune microenvironment

Bile Acids and Microbiota: Multifaceted and Versatile Regulators of the Liver–Gut Axis

The influence of bile acid, microbiota and their interaction on inflammatory bowel disease and the related progress in clinical application

Gut microbiota-related bile acid metabolism-FXR/TGR5 axis impacts the response to anti-α4β7-integrin therapy in humanized mice with colitis

Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis

The Role of Gut Microbiota-Derived Lithocholic Acid, Deoxycholic Acid and Their Derivatives on the Function and Differentiation of Immune Cells

The Gut Microbiota as a Therapeutic Target in IBD and Metabolic Disease: A Role for the Bile Acid Receptors FXR and TGR5

Bile acids and their receptors in regulation of gut health and diseases

The role of bile acids in regulating glucose and lipid metabolism.

Effect of different bile acids on the intestine through enterohepatic circulation based on FXR

Exploring the role of a novel postbiotic bile acid: Interplay with gut microbiota, modulation of the farnesoid X receptor, and prospects for clinical translation

Emerging roles of bile acids in control of intestinal functions

Role of bile acids in liver diseases mediated by the gut microbiome

Bile Acids and the Gut Liver Axis

Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity

The interaction of bile acids and gut inflammation influences the pathogenesis of inflammatory bowel disease

Bile Acids Activated Receptors in Inflammatory Bowel Disease

Targeting gut microbial bile salt hydrolase (BSH) by diet supplements: new insights into dietary modulation of human health.

Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis

Bile acid and its bidirectional interactions with gut microbiota: a review

The role of bile acid receptor TGR5 in regulating inflammatory signalling